Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Finance

26 Aug 2023

GH Research Reports Q2 2023 Financial Results and Business Update

GH Research has reported its second quarter 2023 financial results, with updates on trials and cash on hand....

By Microdose NewsDesk
psychedelic news

Don’t Miss

21 Aug 2023

News You Might Have Missed: Aug 21st, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk
mushrooms

Breaking News

16 Aug 2023

COMPASS Pathways Announces Capital Raise of Up to $285 Million

COMPASS Pathways has announced a capital raise of up to $285 million, the largest cash injection the industry has seen in quite some time....

By Microdose NewsDesk
mushrooms

Finance

15 Aug 2023

MindMed Secures $50 Million Loan From K2 HealthVentures

MindMed secures $50 Million credit facility with K2 HealthVentures, giving company access to additional capital...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

psychedelic news

Don’t Miss

14 Aug 2023

News You Might Have Missed: Aug 14th, 2023

A weekly roundup of psychedelic medicine news to help you catch up and stay informed. Highlights include news from atai Life Sciences and new psychedelic research....

By Microdose NewsDesk

Industry

10 Aug 2023

First Professional Practice Guidelines Published for Psychedelic-Assisted Therapy

The American Psychedelic Practitioners Association (APPA) has released the first-ever set of professional practice guidelines for psychedelic-assisted therapy....

By Microdose NewsDesk

Breaking News, Industry

9 Aug 2023

atai Life Sciences Announces Results of New Phase 1 Study of PCN-101 (R-Ketamine)

Atai announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine)....

By Microdose NewsDesk

Industry

8 Aug 2023

Filament Health Announces FDA Approval of Two Clinical Trials

FDA has approved two clinical trials studying the effects of PEX010, Filament's botanical psilocybin drug candidate....

By Microdose NewsDesk

Industry

8 Aug 2023

Algernon NeuroScience Announces Phase 2 DMT Stroke Study

Algernon NeuroScience has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.